ORAL ITRACONAZOLE FOR THE TREATMENT OF SEVERE SEBORRHOEIC DERMATITIS

BACKGROUND: Seborrheic dermatitis (SD) is an inflammatory skin disorder in which colonies of Malassezia furfur have been found in affected areas. AIM: The aim of this study was to evaluate the efficacy of itraconazole in the treatment of severe SD. MATERIALS AND METHODS: Itraconazole was given to 30...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Jayasri, Majumdar, Monalisa, Chakraborty, Urmita, Majumdar, Vivek, Mazumdar, Gautam, Nath, Jayasree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Therapeutic Round
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221212/
https://www.ncbi.nlm.nih.gov/pubmed/22121267
http://dx.doi.org/10.4103/0019-5154.87137
Descripción
Sumario:BACKGROUND: Seborrheic dermatitis (SD) is an inflammatory skin disorder in which colonies of Malassezia furfur have been found in affected areas. AIM: The aim of this study was to evaluate the efficacy of itraconazole in the treatment of severe SD. MATERIALS AND METHODS: Itraconazole was given to 30 patients of SD in a dose of 100 mg twice daily for 1 week followed by 200 mg/day for first 2 days of the following 2 months. The response was noted on day 15, 30, 60, and 90. The clinical response was graded as markedly effective, effective, or ineffective. RESULTS: Clinical improvement (evaluated as markedly effective or effective) was observed in 83.3% cases. CONCLUSION: The anti-inflammatory activity of oral itraconazole suggests that it should be the first-line therapy in severe SD.

Ejemplares similares